Core Viewpoint - Qingdao Baiyang Pharmaceutical Co., Ltd. has signed a deepened cooperation agreement with CSL, granting exclusive promotion, sales, and distribution rights for CSL's human albumin product, AmbuM, in specific markets within mainland China [1][2]. Group 1: Company Overview - Baiyang Pharmaceutical is expanding its collaboration with CSL, building on their previous partnership in the retail market established in 2018 [1]. - The company aims to leverage its established market network in liver disease treatment to provide comprehensive solutions for patients [3]. Group 2: Industry Insights - Human albumin is the largest therapeutic drug market in China, exceeding 30 billion yuan, with a long-standing dominance of imported products [2]. - CSL holds a significant market share of nearly 24% in the human albumin sector in China [2]. - The market for human albumin is projected to grow to 57 billion yuan by 2030, with a compound annual growth rate of 6.0% from 2025 to 2030 [2]. - AmbuM is specifically designed for the Chinese market, with a key advantage of being stored at temperatures not exceeding 30°C, enhancing drug accessibility and supply chain resilience [2].